Literature DB >> 20824908

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

Jonathan M Plumb, Andreas Clemens, Brigitta U Monz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20824908     DOI： 10.2165/11535700-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  14 in total

Review 1.  Recent developments in the use of oral anticoagulants.

Authors:  Michael R Lassen
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

2.  Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.

Authors:  S E Wolowacz; N S Roskell; J M Plumb; A Clemens; H Noack; P A Robinson; G Dolan; I J Brenkel
Journal:  Thromb Haemost       Date:  2009-12-18       Impact factor: 5.249

Review 3.  Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

Authors:  Alok Kapoor; Warren Chuang; Nila Radhakrishnan; Kenneth J Smith; Dan Berlowitz; Jodi B Segal; Jeffrey N Katz; Elena Losina
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

Authors:  B I Eriksson; O E Dahl; N Rosencher; A A Kurth; C N van Dijk; S P Frostick; P Kälebo; A V Christiansen; S Hantel; R Hettiarachchi; J Schnee; H R Büller
Journal:  J Thromb Haemost       Date:  2007-11       Impact factor: 5.824

Review 5.  State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis.

Authors:  Russell D Hull; Roger D Yusen; David Bergqvist
Journal:  Clin Appl Thromb Hemost       Date:  2009-07-15       Impact factor: 2.389

Review 6.  New anticoagulants: focus on venous thromboembolism.

Authors:  Antonio Gómez-Outes; Ramón Lecumberri; Carmen Pozo; Eduardo Rocha
Journal:  Curr Vasc Pharmacol       Date:  2009-07       Impact factor: 2.719

7.  Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Authors:  Bengt I Eriksson; Lars C Borris; Richard J Friedman; Sylvia Haas; Menno V Huisman; Ajay K Kakkar; Tiemo J Bandel; Horst Beckmann; Eva Muehlhofer; Frank Misselwitz; William Geerts
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

Review 8.  Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.

Authors:  Geno Merli; Alex C Spyropoulos; Joseph A Caprini
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

9.  A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

Authors:  Laura McCullagh; Lesley Tilson; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

Authors:  Sorrel E Wolowacz; Neil S Roskell; Fiona Maciver; Stephen M Beard; Paul A Robinson; Jonathan M Plumb; Gerry Dolan; Ivan J Brenkel
Journal:  Clin Ther       Date:  2009-01       Impact factor: 3.393
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.